Home/ Stocks/ BRNS

Barinthus Biotherapeutics plc American Depositary Shares

BRNS XNAS

$0.60 +0.03 (+6.02%) ▲ 15-min delayed

Open

$0.58

High

$0.60

Low

$0.55

Volume

34.9K

Market Cap

$23.08M

About Barinthus Biotherapeutics plc American Depositary Shares

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 14 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$506.0K	$-66,458,000	$-1.64
FY 2025	$506.0K	$-66,458,000	$-1.64
Q3 2025	$156.0K	$-14,571,000	$-0.36
Q2 2025	$13.0K	$-21,126,000	$-0.52

Earnings & Analyst Ratings

Next Earnings: Thu, Nov 5, 2026

Calendar →

Related Market News

No specific coverage for BRNS yet. Check out our latest market news or earnings calendar.

Get BRNS Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Barinthus Biotherapeutics plc American Depositary Shares.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.